Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03499483 · ClinicalTrials.gov registry record · Phase 4
Biktarvy for Non-Occupational Post-Exposure Prophylaxis (nPEP)
A Phase 4 study, sponsored by Fenway Community Health.
- Completed
- Registry status
- Phase 4
- Development phase
- 52
- Enrollment target
NCT03499483 is a Phase 4 study that has completed, run by Fenway Community Health. The registered enrollment target is 52 participants.
The verdict
NCT03499483, a Phase 4 study, has completed, sponsored by Fenway Community Health.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 52 participants
- Enrollment target
Study Summary
Study will evaluate the safety and tolerability of once daily Biktarvy for 28 days for prevention of HIV infection in HIV-1-seronegative adults after high-risk sexual contact. (non-occupational post exposure prophylaxis - nPEP)
Interventions
- DRUG bictegravir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2019-01-24 |
| Est. Completion | 2020-03-31 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03499483
The ClinicalTrials.gov registry entry for NCT03499483 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Fenway Community Health, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which bictegravir is the first listed.
NCT03499483 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03499483 about?
NCT03499483 is a clinical study titled "Biktarvy for Non-Occupational Post-Exposure Prophylaxis (nPEP)". Study will evaluate the safety and tolerability of once daily Biktarvy for 28 days for prevention of HIV infection in HIV-1-seronegative adults after high-risk sexual contact. (non-occupational post exposure prophylaxis - nPEP)
What is the current status of trial NCT03499483?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 52 participants. The study started on 2019-01-24. Estimated completion is 2020-03-31.
What interventions are being tested in trial NCT03499483?
The interventions under investigation include: bictegravir (DRUG).
Who is sponsoring clinical trial NCT03499483?
This trial is sponsored by Fenway Community Health, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.